Cargando…

Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation

OBJECTIVE: Gut microbiota might play a crucial role in the pathogenesis of irritable bowel syndrome (IBS), and probiotics supplement may be an effective treatment option. This study aims to explore the therapeutic effects of Golden bifid on the diarrhea-predominant IBS (IBS-D). METHODS: Twenty-one c...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Mei, Liu, Qin, Xiao, Lin, Xiong, Li-Shou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109320/
https://www.ncbi.nlm.nih.gov/pubmed/35578355
http://dx.doi.org/10.1186/s41043-022-00302-0
_version_ 1784708876178817024
author Luo, Mei
Liu, Qin
Xiao, Lin
Xiong, Li-Shou
author_facet Luo, Mei
Liu, Qin
Xiao, Lin
Xiong, Li-Shou
author_sort Luo, Mei
collection PubMed
description OBJECTIVE: Gut microbiota might play a crucial role in the pathogenesis of irritable bowel syndrome (IBS), and probiotics supplement may be an effective treatment option. This study aims to explore the therapeutic effects of Golden bifid on the diarrhea-predominant IBS (IBS-D). METHODS: Twenty-one consecutive IBS-D patients were recruited based on Rome IV criteria. All patients took 2000 mg Golden bifid triple daily for 4 weeks. Gastrointestinal (GI) symptoms, psychological symptoms, small intestine bacterial overgrowth (SIBO) and fecal microbiota characteristics were evaluated in IBS-D patients before and after treatment. RESULTS: After 4-week treatment of Golden bifid, the GI symptoms such as abdominal pain (2.90 ± 1.04 vs. 1.90 ± 1.26, P = 0.002), abdominal distension (2.00 ± 1.34 vs. 1.29 ± 1.31, P = 0.007), diarrhea (3.24 ± 1.37 vs. 1.81 ± 1.21, P = 0.001), defecatory urgency (3.48 ± 1.03 vs. 2.33 ± 1.35, P = 0.000) and incomplete evacuation (2.71 ± 1.15 vs. 1.76 ± 1.26, P = 0.003) were significantly alleviated in IBS-D patients. The Self-Rating Depression Scale (SDS) decreased significantly (46.19 ± 11.36 vs. 43.33 ± 9.65, P = 0.041), and SIBO could be eradicated in 25% (4/16) of IBS-D patients with SIBO. Meanwhile, the abundance of Unclassified Lachnospiraceae and Dorea in genus level and Unclassified Lachnospiraceae, Bacterium Dorea, Bacterium Butyricicoccus and Dorea formicigenerans ATCC 27755 in species level were increased in fecal microbiota (P < 0.05). CONCLUSIONS: Golden bifid could improve most of GI symptoms and depressive symptoms in IBS-D patients and eradicate a small proportion of SIBO in those IBS-D patients with SIBO. What's more, Golden bifid could also modulate the fecal microbiota in IBS-D patients, which implied that the Golden bifid might improve IBS-D via microbiota modulation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41043-022-00302-0.
format Online
Article
Text
id pubmed-9109320
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91093202022-05-17 Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation Luo, Mei Liu, Qin Xiao, Lin Xiong, Li-Shou J Health Popul Nutr Research OBJECTIVE: Gut microbiota might play a crucial role in the pathogenesis of irritable bowel syndrome (IBS), and probiotics supplement may be an effective treatment option. This study aims to explore the therapeutic effects of Golden bifid on the diarrhea-predominant IBS (IBS-D). METHODS: Twenty-one consecutive IBS-D patients were recruited based on Rome IV criteria. All patients took 2000 mg Golden bifid triple daily for 4 weeks. Gastrointestinal (GI) symptoms, psychological symptoms, small intestine bacterial overgrowth (SIBO) and fecal microbiota characteristics were evaluated in IBS-D patients before and after treatment. RESULTS: After 4-week treatment of Golden bifid, the GI symptoms such as abdominal pain (2.90 ± 1.04 vs. 1.90 ± 1.26, P = 0.002), abdominal distension (2.00 ± 1.34 vs. 1.29 ± 1.31, P = 0.007), diarrhea (3.24 ± 1.37 vs. 1.81 ± 1.21, P = 0.001), defecatory urgency (3.48 ± 1.03 vs. 2.33 ± 1.35, P = 0.000) and incomplete evacuation (2.71 ± 1.15 vs. 1.76 ± 1.26, P = 0.003) were significantly alleviated in IBS-D patients. The Self-Rating Depression Scale (SDS) decreased significantly (46.19 ± 11.36 vs. 43.33 ± 9.65, P = 0.041), and SIBO could be eradicated in 25% (4/16) of IBS-D patients with SIBO. Meanwhile, the abundance of Unclassified Lachnospiraceae and Dorea in genus level and Unclassified Lachnospiraceae, Bacterium Dorea, Bacterium Butyricicoccus and Dorea formicigenerans ATCC 27755 in species level were increased in fecal microbiota (P < 0.05). CONCLUSIONS: Golden bifid could improve most of GI symptoms and depressive symptoms in IBS-D patients and eradicate a small proportion of SIBO in those IBS-D patients with SIBO. What's more, Golden bifid could also modulate the fecal microbiota in IBS-D patients, which implied that the Golden bifid might improve IBS-D via microbiota modulation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41043-022-00302-0. BioMed Central 2022-05-16 /pmc/articles/PMC9109320/ /pubmed/35578355 http://dx.doi.org/10.1186/s41043-022-00302-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Luo, Mei
Liu, Qin
Xiao, Lin
Xiong, Li-Shou
Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation
title Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation
title_full Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation
title_fullStr Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation
title_full_unstemmed Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation
title_short Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation
title_sort golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109320/
https://www.ncbi.nlm.nih.gov/pubmed/35578355
http://dx.doi.org/10.1186/s41043-022-00302-0
work_keys_str_mv AT luomei goldenbifidmightimprovediarrheapredominantirritablebowelsyndromeviamicrobiotamodulation
AT liuqin goldenbifidmightimprovediarrheapredominantirritablebowelsyndromeviamicrobiotamodulation
AT xiaolin goldenbifidmightimprovediarrheapredominantirritablebowelsyndromeviamicrobiotamodulation
AT xionglishou goldenbifidmightimprovediarrheapredominantirritablebowelsyndromeviamicrobiotamodulation